$Amazing $Biotech & $olid $Microcap $tocks

[ash111]

$AYTU DD:
Solid balance sheet. Company trading at only $8m post R/S ( 1.8m O/S). Past 10Q: $12m Cash on hand (vs $3m back in June 2017) + a few more restricted cash, w/ about $4m cash Burn rate, should be sufficient thru upcoming major Phase 3 data later this year. Fits my risk/reward agenda to hold thru bid data. A "half" lotto that could make AQXP's run back in 2015, from $1 to $50 ( check Ibox for alert). Almost all fits, Phase 3, cash on hand, float, even market cap/potential .

Company products under the spotlight these days:

Tesla's Elon Musk works 120 hours a week, uses Ambien to sleep
https://t.co/RzIzNJCZlP

Drugmakers continue price increases: Aytu BioScience recently bought rights to a spray form of Ambien and then raised the price as much as 843% https://t.co/Dkn6PJQ2SS via @WSJ

" the biggest price increase this month -- of more than 700 percent --came from tiny Aytu BioScience Inc., for an obscure sleep drug called Zolpimist" https://t.co/sSM4gwBgBf

CEO ...

“if we only achieved 5% penetration in each of these markets, that would be approximately $90 to $100M net revenue. A rationally-valued specialty pharma comp would be valued at 3 to 5 times net revenue, so that would approximate a $300M to $500”